Antiviral activity of selected antimicrobial peptides against vaccinia virus

Antiviral Research

Volumn 86, Issue 3, 2010, Pages 306-311

  Mohan, Ketha V K ^a   Rao, Shilpakala Sainath ^a   Atreya, Chintamani D ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

AMPs; Microbicidal; Pfu; Platelet derived peptides; RW peptides

Indexed keywords

ARGININE TRYPTOPHAN PEPTIDE DERIVATIVE; PLATELET DERIVED POLYPEPTIDE ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS PLAQUE; VIRUS STRAIN;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE; CERCOPITHECUS AETHIOPS; HUMANS; MICROBIAL VIABILITY; PLAQUE ASSAY; VACCINIA VIRUS;

VACCINIA VIRUS;

EID: 77952675019     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.03.012     Document Type: Article

References (35)

1. Ahmed C.M., Burkhart M.A., Subramaniam P.S., Mujtaba M.G., Johnson H.M. Peptide mimetics of gamma interferon possess antiviral properties against vaccinia virus and other viruses in the presence of poxvirus B8R protein. J. Virol. 2005, 79:5632-5639.
2. Altmann S.E., Jones J.C., Schultz-Cherry S., Brandt C.R. Inhibition of vaccinia virus entry by a broad spectrum antiviral peptide. Virology 2009, 388:248-259.
3. Bai F., Town T., Pradhan D., Cox J., Ashish, Ledizet M., Anderson J.F., Flavell R.A., Krueger J.K., Koski R.A., Fikrig E. Antiviral peptides targeting the west nile virus envelope protein. J. Virol. 2007, 81:2047-2055.
4. Basu D., Walkiewicz M.P., Frieman M., Baric R.S., Auble D.T., Engel D.A. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J. Virol. 2009, 83:1881-1891.
5. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 2005, 3:238-250.
6. Chan D.I., Prenner E.J., Vogel H.J. Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta 2006, 1758:1184-1202.
7. Chu L.H., Chan S.H., Tsai S.N., Wang Y., Cheng C.H., Wong K.B., Waye M.M., Ngai S.M. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. J. Cell Biochem. 2008, 104:2335-2347.
8. Daher K.A., Selsted M.E., Lehrer R.I. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 1986, 60:1068-1074.
9. Dorschner R.A., Pestonjamasp V.K., Tamakuwala S., Ohtake T., Rudisill J., Nizet V., Agerberth B., Gudmundsson G.H., Gallo R.L. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 2001, 117:91-97.
10. Gallo R.L., Murakami M., Ohtake T., Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol. 2002, 110:823-831.
11. Groneberg D.A., Fischer A., Chung K.F., Daniel H. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am. J. Respir. Cell Mol. Biol. 2004, 30:251-260.
12. Guo Y., Tisoncik J., McReynolds S., Farzan M., Prabhakar B.S., Gallagher T., Rong L., Caffrey M. Identification of a new region of SARS-CoV S protein critical for viral entry. J. Mol. Biol. 2009, 394:600-605.
13. Hancock R.E., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24:1551-1557.
14. Harder J., Bartels J., Christophers E., Schroder J.M. A peptide antibiotic from human skin. Nature 1997, 387:861.
15. Harrison J.M., Ramshaw I.A. Cytokines, skin, and smallpox-a new link to an antimicrobial peptide. Immunity 2006, 24:245-247.
16. Howell M.D., Jones J.F., Kisich K.O., Streib J.E., Gallo R.L., Leung D.Y. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 2004, 172:1763-1767.
17. Howell M.D., Streib J.E., Kim B.E., Lesley L.J., Dunlap A.P., Geng D., Feng Y., Savage P.B., Leung D.Y. Ceragenins: a class of antiviral compounds to treat orthopox infections. J. Invest. Dermatol. 2009, 129:2668-2675.
18. Howell M.D., Streib J.E., Leung D.Y. Antiviral activity of human beta-defensin 3 against vaccinia virus. J. Allergy Clin. Immunol. 2007, 119:1022-1025.
19. Jones-Trower A., Garcia A., Meseda C.A., He Y., Weiss C., Kumar A., Weir J.P., Merchlinsky M. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology 2005, 343:128-140.
20. Kotwal G.J., Hugin A.W., Moss B. Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 1989, 171:579-587.
21. Lin L., Hanson C.V., Alter H.J., Jauvin V., Bernard K.A., Murthy K.K., Metzel P., Corash L. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005, 45:580-590.
22. Liu Z., Brady A., Young A., Rasimick B., Chen K., Zhou C., Kallenbach N.R. Length effects in antimicrobial peptides of the (RW)n series. Antimicrob. Agents Chemother. 2007, 51:597-603.
23. Mohan K.V., Rao S.S., Atreya C.D. Evaluation of antimicrobial peptides as novel bactericidal agents for room temperature-stored platelets. Transfusion 2009.
24. Mohan K.V., Zhang C.X., Atreya C.D. The proteoglycan bamacan is a host cellular ligand of vaccinia virus neurovirulence factor N1L. J. Neurovirol. 2009, 1-9.
25. Oyston P.C., Fox M.A., Richards S.J., Clark G.C. Novel peptide therapeutics for treatment of infections. J. Med. Microbiol. 2009, 58:977-987.
26. Remington K.M., Trejo S.R., Buczynski G., Li H., Osheroff W.P., Brown J.P., Renfrow H., Reynolds R., Pifat D.Y. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang. 2004, 87:10-18.
27. Roberts P. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals 2000, 28:29-32.
28. Saccucci L., Crance J.M., Colas P., Bickle M., Garin D., Iseni F. Inhibition of vaccinia virus replication by peptide aptamers. Antiviral Res. 2009, 82:134-140.
29. Snyder E.L., Dowdy S.F. Cell penetrating peptides in drug delivery. Pharm. Res. 2004, 21:389-393.
30. Srinivasan K., Akolkar P.N., Taffs R.E., Hewlett I.K. Absence of detectable viremia in plasma and peripheral blood mononuclear cells from smallpox vaccinees: implications for blood safety. Transfusion 2006, 46:1589-1592.
31. Tang Y.Q., Yeaman M.R., Selsted M.E. Antimicrobial peptides from human platelets. Infect. Immun. 2002, 70:6524-6533.
32. Wu Y.Y., Snyder E.L. Safety of the blood supply: role of pathogen reduction. Blood Rev. 2003, 17:111-122.
33. Yeaman M.R., Bayer A.S. Antimicrobial peptides from platelets. Drug Resist. Updat. 1999, 2:116-126.
34. Yeaman M.R., Yount N.Y., Waring A.J., Gank K.D., Kupferwasser D., Wiese R., Bayer A.S., Welch W.H. Modular determinants of antimicrobial activity in platelet factor-4 family kinocidins. Biochim. Biophys. Acta 2007, 1768:609-619.
35. Zaiou M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J. Mol. Med. 2007, 85:317-329.